Skip to main content

Investor Center

Corporate Profile

Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
Presentations
Recent Press Releases
December 8, 2024
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of  Hemoglobin F mAb Dosing Well Tolerated Without Need for Supportive Care Beam on Track to Initiate Phase 1-enabling Studies
Read More
Events/Webcasts

Stock Quote

Common Stock

Price

Change (%)

Volume

Data as of 01/06/25 2:47 AM EST. Refreshes every 15 minutes.

Minimum 15 minutes delayed. Source: LSEG